Videos

Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.

Dr Bose engages with emergent trial data presented at the American Society of Hematology (ASH) 2022 Annual Meeting.

Prithviraj Bose, MD discusses typical patient outcomes in PV and other myeloproliferative neoplasms, emphasizing the importance of patient priorities and symptom management.

A practical approach to patient monitoring, with a focus on assessing treatment efficacy and individualized patient care.

A review of available treatments, treatment selection, and treatment sequencing for patients with PV as informed by clinical trial data.

Subject matter expert reviews biological mechanisms underpinning myeloproliferative neoplasms and standard-of-care risk assessment for patients with PV.

Closing out her discussion on the treatment and management of HR+/HER2- mBC, Hope Rugo, MD, FASCO, highlights unmet needs and future directions in the field.

Dr Hope Rugo shares insight on how she approaches second-line and higher treatment selection in patients with HR+/HER2- metastatic breast cancer who experience disease progression on first-line therapy.

Centering discussion on the EMERALD trial, Dr Hope Rugo, reflects on the safety and efficacy of elacestrant in patients with HR+/HER2- mBC.

A comprehensive review of treatment options for patients with HR+/HER2- metastatic breast cancer who experience disease progression on standard-of-care therapies such as combination CDK4/6 and aromatase inhibitors.

Expert perspective on the role of ESR1 mutations in HR+/HER2- mBC and best practices on biomarker testing for patients experiencing disease progression on endocrine therapy.

Expert oncologist Hope Rugo, MD, FASCO, reviews the diagnosis and treatment of a 57-year-old woman with HR+/HER2- metastatic breast cancer (mBC).

Patrick Wen, MD, looks at how emerging evidence has shown promise for targeting mutations in patients with glioblastomas when it was once believed these therapies may not work for these patients.

Dr Bose shares his initial impressions of a PV patient case before discussing typical patient presentation and criteria for PV diagnosis.

Dr Ana Velázquez Mañana introduces a second patient case, a 59-year-old Black man diagnosed with mNSCLC and an EGFR exon 20 insertion, and outlines first-line treatment selection for the patient.

Prithviraj Bose, MD introduces a polycythemia vera (PV) patient case featuring a 67-year-old man presenting with frequent headaches and dizziness.

Expert panelists react to the presented data on racial and socioeconomic disparities in biomarker testing for patients with mNSCLC, and align on ways to address and overcome these disparities.

A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.

Comprehensive discussion on molecular testing strategies utilized in non–small cell lung cancer to help inform treatment decisions.

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

Nitin Jain, MD, discusses future improvements he anticipates for autologous and allogeneic chimeric antigen receptor T-cell therapies for B-cell acute lymphoblastic leukemia and other hematologic malignancies.

Yuri E. Nikiforov, MD, PhD, discusses the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which has significantly influenced the thyroid cancer space.

Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.

Krina Patel, MD, MSc, presents the case of a 65-year-old woman with relapsed/refractory multiple myeloma, and the panel discusses the optimal sequencing of her treatment regimens.

Closing out his discussion on chronic graft-vs-host disease, Yi-Bin Chen, MD, looks to the future of GVHD treatment.

Yi-Bin-Chen, MD, discusses the effect of GVHD recurrence and multiple-organ involvement on treatment decisions.

A summary of the systemic treatment options available for steroid-refractory chronic GVHD.

A comprehensive overview of the various treatment options for chronic graft-vs-host disease.

Yi-Bin Chen, MD, describes acute and chronic GVHD, and details the typical symptoms and presentations.